Forgot Password?
Return to Course Listing

CME: Optimizing Primary and Secondary Fracture Prevention in Men with Osteoporosis

Activity Description / Statement of Need:

In this online CME self-learning activity:

Osteoporosis is characterized by low bone mass and deterioration of bone tissues, which leads to an increased risk of skeletal fractures. Although generally considered a women’s health issue, osteoporosis in men is an important public health issue. ~1- 2 million men in the United States have been estimated to have clinical osteoporosis, and an additional 8 - 13 million men identified to have low bone mass. Despite osteoporosis being frequently overlooked in this population,men account for 29% of the total osteoporotic fractures in the United States and 25% of the total cost of treatment.Morbidity and mortality associated with fracture are higher in men than women, with almost a three-times higher mortality rate associated with hip fracture.However, despite the significant implications for men’s health, male osteoporosis remains largely overlooked. One study found that less than 9% of men 70 years of age or older reported being screened for osteoporosis, and only two-thirds of physicians reported regularly screening men for osteoporosis.

Target Audience:

The following healthcare professionals: Primary care physicians and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with male osteoporosis.


Commercial Support Disclosure: This activity is supported by an educational grant from Radius Pharmaceuticals.

Learners may participate in this activity free of charge.


Release Date: May 23, 2020 -- Expiration Date: May 23, 2022

Faculty: Azeez Farooki, MD

Agenda

Faculty introduction, disclosures

Introduction content: Cursory review of male osteoporosis and fracture assessment

  • Epidemiology of male osteoporosis
  • Defining clinical features and risk factors
  • Guidelines for fracture risk assessment (measuring BMD by DXA, FRAX scores)
    • Case study: Patient #1

Preventing secondary fracture in men with osteoporosis

  • Clinical guidelines for treatment of male osteoporosis and prevention of secondary fracture
  • Review of current classes of pharmacotherapy and role in preventing fracture
    • Case study: Patient #2
  • Investigational therapies and mechanisms of action
  • Management of risk factors for falling
  • FRIDs commonly prescribed in the elderly
    • Case study: Patient #3

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Apply primary and secondary fracture assessments to male patients with osteoporosis.
  • Identify present pharmacotherapeutic treatments for management of male osteoporosis, describe their mechanisms of action and place in therapy, and apply the information to develop a pharmacological treatment plan in a patient case.
  • Describe investigational pharmacotherapeutic treatments for management of male osteoporosis and secondary fracture prevention, and describe their mechanisms of action and likely place in therapy.
  • Describe the steps patients can take to reduce the risk of falling, as well as the role healthcare providers play in fall prevention and apply the information to a patient case.

Accreditation

ACCME Activity #201861254

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Azeez Farooki, MD, Associate Attending Physician, Endocrinology Service, MSKCC, has no relevent financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
 
Commercial Support Disclosure: This activity is supported by an educational grant from Radius Pharmaceuticals.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Postmenopausal osteoporosis risk stratification and treatment of those at high risk for fracture

The current and emerging landscape of pediatric growth hormone deficiency (GHD) pharmacotherapy

Hypoparathyroidism: Optimizing pharmacotherapeutic management strategies